We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
At West, our goal is to partner with customers to mitigate risks of drug/packaging incompatibility, container/device and functional challenges. Although we consider critical quality attributes during development of drug packaging and delivery systems, there can be knowledge gaps of various interfaces based on the specific application of use, such as component-to-container, container-to-device, and container-to-drug.
Formed in 2016, Scientific Insights Lab brings together experts with broad knowledge and experience in polymer materials, surface science, biologic drugs and computational modeling. We help customers understand, select, optimize and improve container closure system targeting specific to their drug product applications and manufacturing process.
Our comprehensive protein testing capabilities include:
We also perform surface analytical and functionality testing capabilities to assess drug impacts on containers over time. Using theoretical prediction and experimental verification, we assist our customers to predict long term container/drug compatibility at the early stage of combination product development.
Finally, we can perform container closure system (CCS) compatibility and optimization testing for high-quality performance. When used in combination with the comprehensive container closure integrity (CCI) testing methods, our experts can serve customers with
By partnering together, West’s experts offer customers the ability to understand the interactions of containers and their new drug products, to provide solutions of container closure systems to mitigate risks down the road in a close, collaborative customer relationship.
Learn more by watching our video above or visiting our featured video channel for additional videos!
#WestByYourSide #SimplifytheJourney
The definitions of <em>personalized medicine</em> vary. However, all of them indicate that the once popular therapy approach of “<em>one drug fits all</em>” is outdated. The Council of the European Union defines personalized medicine as <em>“[p]roviding the right treatment to the right patient, at the right dose at the right time.”</em><sup>[1]</sup>.
Quality. Technology. Trends in manufacturing. Injection systems. Primary containers. Global market trends. What does each of these areas have in common? Over the past decade tremendous progress has been made in drug delivery, but challenges continue.
Many of the top-selling biologic drug products will soon come off-patent. As a result, according to IMS, the biosimilar market is expected to reach between US$1.9-2.6 billion by 2015.
West is proud to announce that we have published our 2021 Corporate Responsibility (CR) Report, Purpose. Driven., which is now available on <a href="/es-es/about-west/corporate-responsibility">West’s website.</a> <br />This is West’s 6<sup>th</sup> annual CR Report, and highlights ESG successes from over the past year, including progress on environmental sustainability goals, diversity and inclusion, and success around the Company’s philanthropic efforts. The publication also highlights some of the recognition received for our ESG (Environmental, Social, Governance) performance, including placement in Barron’s Top 100 Most Sustainable Companies, Corporate Social Responsibility Programme of the Year from Pharma Industry Awards in Ireland, and a Silver Stevie Award for Corporate Social Responsibility.
Moving can be tough business. When West relocated its global headquarters to a new facility in Exton, Pennsylvania, associates had a lot of cleaning to do. Efforts were made to recycle business materials that were no longer needed in our newer, greener location.
English
Chinese
